The most common treatment-related adverse events (occurring in >15 % of patients) were infusion-related reaction and neutropenia (8 patients; 42 %, each), leukopenia (7 patients; 37 %), thrombocytopenia (6 patients; 32 %), AST increased, fatigue, nausea, and vomiting (4 patients; 21 %, each), ALT increased, lymphopenia, rash, and stomatitis (3 patients; 16 %, each). The gene discussed is GPT; the disease is Decreased total neutrophil count.